...
首页> 外文期刊>Molecular cancer therapeutics >Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.
【24h】

Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.

机译:组蛋白脱乙酰基酶的选择性抑制使恶性细胞对死亡受体配体敏感。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Evasion of death receptor ligand-induced apoptosis represents an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better understand this biological pathway and potential leads for therapeutic adjuncts. Previously, the small-molecule 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide (that we propose be named droxinostat) was identified as a chemical sensitizer to death receptor stimuli, decreasing the expression of the caspase-8 inhibitor FLIP. However, the direct targets of droxinostat were unknown. To better understand the mechanism of action of droxinostat and highlight new strategies to restore sensitivity to death receptor ligands, we analyzed changes in gene expression using the Connectivity Map after treating cells with droxinostat. Changes in gene expression after droxinostat treatment resembled changes observed after treatment with histone deacetylase (HDAC) inhibitors. Therefore, we examined the effects of droxinostat on HDAC activity and showed that it selectively inhibited HDAC3, HDAC6, and HDAC8 and that inhibition of these HDACs was functionally important for its ability to sensitize cells to death ligands. Thus, we have identified a selective HDAC inhibitor and showed that selective HDAC inhibition sensitizes cells to death ligands, thereby highlighting a new mechanism to overcome resistance to death receptor ligands.
机译:逃避死亡受体配体诱导的细胞凋亡代表了癌症发展和进展的重要贡献。因此,恢复对死亡受体刺激的敏感性的分子将是更好地了解该生物学途径和治疗辅助手段的潜在工具的重要工具。以前,小分子4-(4-氯-2-甲基苯氧基)-N-羟基丁酰胺(我们建议命名为Droxinostat)被鉴定为对死亡受体刺激的化学敏化剂,从而降低了caspase-8抑制剂FLIP的表达。 。但是,尚不知道Droxinostat的直接目标。为了更好地了解Droxinostat的作用机理并强调恢复对死亡受体配体敏感性的新策略,我们在用Droxinostat处理细胞后,使用Connectivity Map分析了基因表达的变化。 Droxinostat治疗后基因表达的变化类似于用组蛋白脱乙酰基酶(HDAC)抑制剂治疗后观察到的变化。因此,我们检查了Droxinostat对HDAC活性的影响,并表明它有选择地抑制HDAC3,HDAC6和HDAC8,并且抑制这些HDAC对功能很重要,因为它具有使细胞对死亡配体敏感的能力。因此,我们已经确定了选择性HDAC抑制剂,并表明选择性HDAC抑制使细胞对死亡配体敏感,从而突出了克服对死亡受体配体的抗性的新机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号